Search research articles
Contact Us
Filters
Showing results (41-50 of 75) with videos related to
Page
of 8
Sort By:
Clinical & Experimental Metastasis
|
August 27, 2013
Melanoma brain metastases: the impact of nodal disease
James E Jackson, Bryan H Burmeister, Elizabeth A Burmeister, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 27, 2007
Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment--"Hypo Trial"
Sandro V Porceddu, Brenda Rosser, Bryan H Burmeister, et al.
Investigational New Drugs
|
October 9, 2008
A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer
Bryan H Burmeister, Euan T Walpole, Nancy D'Arcy, et al.
Journal of Medical Imaging and Radiation Oncology
|
March 19, 2024
Utility of 30-day mortality as a quality metric for palliative radiation treatment: A population-based analysis from Queensland, Australia
Tracey L Guan, Justin H Kutzko, Dominic P Lunn, et al.
International Journal of Clinical Oncology
|
September 2, 2005
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin
Bryan H Burmeister, Euan T Walpole, Elizabeth A Burmeister, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 10, 2005
Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)
Daniel E Roos, Sandra L Turner, Peter C O'Brien, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 8, 2000
A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05)
D E Roos, P C O'Brien, J G Smith, et al.
Australasian Radiology
|
September 7, 2000
Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05)
D E Roos, S R Davis, P C O'Brien, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 29, 2001
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group
S Y Ngan, B H Burmeister, R Fisher, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 19, 2003
Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05)
Daniel E Roos, Sidney R Davis, Sandra L Turner, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 75) with videos related to
Sort By:
Page
of 8
Clinical & Experimental Metastasis
|
August 27, 2013
Melanoma brain metastases: the impact of nodal disease
James E Jackson, Bryan H Burmeister, Elizabeth A Burmeister, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 27, 2007
Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment--"Hypo Trial"
Sandro V Porceddu, Brenda Rosser, Bryan H Burmeister, et al.
Investigational New Drugs
|
October 9, 2008
A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer
Bryan H Burmeister, Euan T Walpole, Nancy D'Arcy, et al.
Journal of Medical Imaging and Radiation Oncology
|
March 19, 2024
Utility of 30-day mortality as a quality metric for palliative radiation treatment: A population-based analysis from Queensland, Australia
Tracey L Guan, Justin H Kutzko, Dominic P Lunn, et al.
International Journal of Clinical Oncology
|
September 2, 2005
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin
Bryan H Burmeister, Euan T Walpole, Elizabeth A Burmeister, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 10, 2005
Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)
Daniel E Roos, Sandra L Turner, Peter C O'Brien, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 8, 2000
A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05)
D E Roos, P C O'Brien, J G Smith, et al.
Australasian Radiology
|
September 7, 2000
Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05)
D E Roos, S R Davis, P C O'Brien, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 29, 2001
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group
S Y Ngan, B H Burmeister, R Fisher, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 19, 2003
Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05)
Daniel E Roos, Sidney R Davis, Sandra L Turner, et al.
Page
of 8